TNF Pharmaceuticals Files 2024 10-K, Details Preferred Stock
Ticker: QCLS · Form: 10-K · Filed: Apr 11, 2025 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 10-K |
| Filed Date | Apr 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, preferred-stock
TL;DR
TNF Pharma's 2024 10-K is in, showing preferred stock details. Check it out.
AI Summary
TNF Pharmaceuticals, Inc. filed its 2024 10-K on April 11, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as MyMD Pharmaceuticals, Inc. and Akers Biosciences, Inc., is involved in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' industry. The filing details various financial instruments, including Series F, Series F-One, and Series G Convertible Preferred Stock, as of December 31, 2024, and 2023.
Why It Matters
This filing provides investors with a comprehensive overview of TNF Pharmaceuticals' financial health and corporate structure for the fiscal year 2024, including details on its preferred stock issuances.
Risk Assessment
Risk Level: medium — The filing is a standard 10-K, but the company has a history of name changes and operates in a regulated industry, which can introduce inherent risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-04-11 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-04-11 (date) — Filing date
- MyMD Pharmaceuticals, Inc. (company) — Former company name
- Akers Biosciences, Inc. (company) — Former company name
- TNFA:SeriesFConvertiblePreferredStockMember (dollar_amount) — Financial instrument detailed
- TNFA:SeriesFOneConvertiblePreferredStockMember (dollar_amount) — Financial instrument detailed
- TNFA:SeriesGConvertiblePreferredStockMember (dollar_amount) — Financial instrument detailed
FAQ
What was TNF Pharmaceuticals, Inc.'s former name before April 20, 2021?
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. as of April 20, 2021.
What is the Standard Industrial Classification code for TNF Pharmaceuticals, Inc.?
The SIC code for TNF Pharmaceuticals, Inc. is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
On what date was this 10-K filing submitted to the SEC?
This 10-K filing was submitted to the SEC on April 11, 2025.
What is the fiscal year end date reported in this 10-K?
The fiscal year end date reported in this 10-K is December 31, 2024.
Which series of convertible preferred stock are detailed in the filing for the fiscal year ending December 31, 2024?
The filing details Series F Convertible Preferred Stock, Series F-One Convertible Preferred Stock, and Series G Convertible Preferred Stock for the fiscal year ending December 31, 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on April 11, 2025 regarding TNF Pharmaceuticals, Inc. (QCLS).